>
Chugai Pharmaceutical Co logo

4519 - Chugai Pharmaceutical Co Share Price

¬•4324 -34.0  -0.8%

Last Trade - 12/04/21

Sector
Healthcare
Size
Large Cap
Market Cap £47.29bn
Enterprise Value £44.85bn
Revenue £5.24bn
Position in Universe 14th / 3900
Bullish
Bearish
Unlock 4519 Revenue
Momentum
Relative Strength (%)
1m -4.28%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -32.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
498,840 491,781 534,199 579,787 686,184 786,946 834,942 824,456 +9.5%
+19.8 -12.2 +35.4 +27.0 +70.3 +36.2 +16.1 -5.83
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, ChugaiPharmaceutical Co Ltd revenues increased 15% to Y786.95B.Net income increased 36% to Y214.73B. Revenues reflectSwitzerland segment increase of 57% to Y347.58B, Otherforeign segment increase of 1% to Y20.41B. Net incomebenefited from Other Total SGA decrease of 6% to Y72.55B(expense), General and Administrative Expenses - Badecrease of 11% to Y21.61B (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 4519
Graphical History

Revenue

4519 Revenue Unlock 4519 Revenue

Net Income

4519 Net Income Unlock 4519 Revenue

Normalised EPS

4519 Normalised EPS Unlock 4519 Revenue

PE Ratio Range

4519 PE Ratio Range Unlock 4519 Revenue

Dividend Yield Range

4519 Dividend Yield Range Unlock 4519 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
4519 EPS Forecasts Unlock 4519 Revenue
Profile Summary

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated March 8, 1943
Public Since March 3, 1956
No. of Shareholders: 34,921
No. of Employees: 7,555
Sector Healthcare
Industry Pharmaceuticals
Index Nikkei 225 , Nikkei 300 ,
Exchange Tokyo Stock Exchange
Shares in Issue 1,643,871,081
Free Float (0.0%)
Eligible for
ISAs
SIPPs
4519 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 4519
Upcoming Events for 4519
Thursday 22nd April, 2021
Q1 2021 Chugai Pharmaceutical Co Ltd Earnings Release
Thursday 22nd April, 2021
Q1 2021 Chugai Pharmaceutical Co Ltd Earnings Call
Thursday 22nd April, 2021
Q1 2021 Chugai Pharmaceutical Co Ltd Earnings Call (Japanese)
Tuesday 29th June, 2021
Dividend For 4519.T - 30.0000 JPY
Monday 26th July, 2021
Q2 2021 Chugai Pharmaceutical Co Ltd Earnings Release
Frequently Asked Questions for Chugai Pharmaceutical Co
What is the Chugai Pharmaceutical Co share price?

As of 12/04/21, shares in Chugai Pharmaceutical Co are trading at ¥4324, giving the company a market capitalisation of £47.29bn. This share price information is delayed by 15 minutes.

How has the Chugai Pharmaceutical Co share price performed this year?

Shares in Chugai Pharmaceutical Co are currently trading at ¥4324 and the price has moved by -5.31% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Chugai Pharmaceutical Co price has moved by -39.43% over the past year.

What are the analyst and broker recommendations for Chugai Pharmaceutical Co?

Of the analysts with advisory recommendations for Chugai Pharmaceutical Co, there are there are currently 0 "buy" , 8 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Chugai Pharmaceutical Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Chugai Pharmaceutical Co next release its financial results?

Chugai Pharmaceutical Co is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Chugai Pharmaceutical Co dividend yield?

The Chugai Pharmaceutical Co dividend yield is 1.27% based on the trailing twelve month period.

Does Chugai Pharmaceutical Co pay a dividend?

Last year, Chugai Pharmaceutical Co paid a total dividend of 55, and it currently has a trailing dividend yield of 1.27%. Looking ahead, shares in Chugai Pharmaceutical Co are due to go ex-dividend on 2021-06-29 and the next dividend pay date is 2021-09-01.

When does Chugai Pharmaceutical Co next pay dividends?

Chugai Pharmaceutical Co are due to go ex-dividend on 2021-06-29 and the next dividend pay date is 2021-09-01. The historic dividend yield on Chugai Pharmaceutical Co shares is currently 1.27%.

How do I buy Chugai Pharmaceutical Co shares?

To buy shares in Chugai Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Chugai Pharmaceutical Co?

Shares in Chugai Pharmaceutical Co are currently trading at ¥4324, giving the company a market capitalisation of £47.29bn.

Where are Chugai Pharmaceutical Co shares listed? Where are Chugai Pharmaceutical Co shares listed?

Here are the trading details for Chugai Pharmaceutical Co:

Country of listing: Japan
Exchange: TYO
Ticker Symbol: 4519
What kind of share is Chugai Pharmaceutical Co?

Based on an overall assessment of its quality, value and momentum, Chugai Pharmaceutical Co is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Chugai Pharmaceutical Co share price forecast 2021?

Shares in Chugai Pharmaceutical Co are currently priced at ¥4324. At that level they are trading at 12.27% discount to the analyst consensus target price of 0.00.

Analysts covering Chugai Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of 151.592 for the next financial year.

How can I tell whether the Chugai Pharmaceutical Co share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chugai Pharmaceutical Co. Over the past six months, the relative strength of its shares against the market has been -23.56%. At the current price of ¥4324, shares in Chugai Pharmaceutical Co are trading at -12.35% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Chugai Pharmaceutical Co PE Ratio?

The Chugai Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 33.13. The shares are currently trading at ¥4324.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Chugai Pharmaceutical Co?

Chugai Pharmaceutical Co's management team is headed by:

Motoo Ueno - VCH
Tatsuro Kosaka - CHM
Shinya Unno - EVP
Keiji Kono - SEO
Hisafumi Okabe - SEO
Osamu Okuda - PRE
Toshiaki Itagaki - CFO
Junichi Ebihara - SEO
Christoph Franz - DRC
Yoichiro Ichimaru - IND
James Sabry - DRC
William Anderson - DRC
Mariko Momoi - IND
Mark Noguchi - SEO
Kazuya Usuda - FID
Who are the major shareholders of Chugai Pharmaceutical Co?

Here are the top five shareholders of Chugai Pharmaceutical Co based on the size of their shareholding:

F. Hoffman La Roche, Ltd. Corporation
Percentage owned: 59.89% (1.01bn shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 3.89% (65.4m shares)
Nomura Asset Management Co., Ltd. Investment Advisor
Percentage owned: 3.06% (51.3m shares)
American Funds EuroPacific Growth Fund Mutual Fund
Percentage owned: 2.55% (42.8m shares)
Nomura NEXT FUNDS Nikkei 225 Exchange Traded Fund Mutual Fund
Percentage owned: 1.79% (30.0m shares)
Similar to 4519
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.